Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Gary M. Owens, MD

home / authors / gary-m-owens-md

Articles

Participating Faculty: Rethinking Heart Failure: Patient Classification and Treatment

November 10th 2022

Rethinking Heart Failure: Patient Classification and Treatment

November 10th 2022

The Spectrum of Progressive Fibrosing Interstitial Lung Disease: Clinical and Managed Care Considerations

Systemic Sclerosis With Associated Interstitial Lung Disease: Management Considerations and Future Directions

Idiopathic Pulmonary Fibrosis: Exploring the Clinical and Economic Implications of the Evolving Treatment Landscape

The Economic Burden and Managed Care Implications of Chronic Inflammatory Demyelinating Polyneuropathy

September 25th 2018

Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management

Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations-The New and Evolving Standards of Care

March 24th 2015

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care Landscape

January 1st 2015

Managed Care Implications in Managing Rheumatoid Arthritis

New FDA Guidance on Biosimilars: Another Step Forward A Payer Perspective

Specialty pharmaceuticals are currently the object of payer focus as one of the major drivers of increased pharmacy spending in 2014 and beyond.

Hepatitis C: New Treatments Emerge in 2014 That Will Have Profound Implications for Payers

March 31st 2014

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.

Reflections on 2013-The First of the Breakthrough Therapies: A Payer Perspective

March 31st 2014

As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.

Participating Faculty: Improving Transitions of Care for Patients With Thromboembolic Disease

March 21st 2014

Improving Transitions of Care for Patients With Thromboembolic Disease

March 20th 2014

Managed Care Aspects of Managing Multiple Sclerosis

November 26th 2013

Translating Clinical Guidelines Into Practice: The Effective and Appropriate Use of Human Growth Hormone

November 24th 2013

The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone Metastases

Prostate cancer is the most common solid organ tumor in men. According to the American Cancer Society, in 2013: about 238,590 new cases of prostate cancer will be diagnosed in the United States; about 29,720 men will die of prostate cancer.

Successful Aging in Men with BPH

Migraine in the Managed Care Environment

Clinician and Payer Issues in Managing Growth Hormone Deficiency

September 1st 2000

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences
AJMC®
All rights reserved.